De novo immunosuppression with mammalian target of rapamycin inhibitors and posttransplantation malignancy in focus.
Flechner
S
S
Urological Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.
Friend
P
P
Campistol
J
J
Weir
M
M
Diekmann
F
F
Russ
G
G
D065095:Calcineurin Inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology* / Q000473:pathology; D009369:Neoplasms / Q000453:epidemiology* / Q000517:prevention & control; D011183:Postoperative Complications / Q000453:epidemiology* / Q000517:prevention & control; D011379:Prognosis; D011494:Protein Kinases / Q000502:physiology*; D016032:Randomized Controlled Trials as Topic; D040242:Risk Reduction Behavior; D020123:Sirolimus / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus